REFERENCES
43
16. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated
interferon-alfa-2a induces complete hematologic and molecular responses with low
toxicity in polycythemia vera. Blood. 2008;112(8):3065–72.
17. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised
response criteria for polycythemia vera and essential thrombocythemia: an ELN and
IWG-MRT consensus project. Blood. 2013;121(23):4778–81.
18. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, et al. A
unified definition of clinical resistance and intolerance to hydroxycarbamide in
polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN)
consensus process. Br J Haematol. 2010;148(6):961–3.
19. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified
definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia:
results of a consensus process by an international working group. Leukemia.
2007;21(2):277–80.
20. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Levy R, et al. Durable
responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera
(PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU).
ASH Annual Meeting Abstracts. 2010;116(21):313.
21. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2
study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced
polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer.
2013;120(4):513–20.
22. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and
management recommendations from European LeukemiaNet. J Clin Oncol.
2011;29(6):761–70.
23. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for
the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453–71.
24. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic
prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT
(International Working Group for Myeloproliferative Neoplasms Research and
Treatment). Blood. 2010;115(9):1703–8.
25. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus:
a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that
incorporates prognostic information from karyotype, platelet count, and transfusion
status. J Clin Oncol. 2011;29(4):392–7.
26. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New
prognostic scoring system for primary myelofibrosis based on a study of the International
Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–
901.
27. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J,et al; BSH Committee. A
guideline for the diagnosis and management of polycythaemia vera. A British
Society for Haematology Guideline. Br J Haematol. 2019 ;184(2):176-191.
Apr;185(1):198.
28. Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C,et al.
Essential thrombocythaemia treated with recombinant interferon: 'real world' United
Kingdom referral centre experience. Br J Haematol; 2019; 186(4):561-564.